Results for:(78 found)
Feb 16, 2012 1:41PM on Top StocksBy TheStockAdvisors

Here's a look at a leader in HIV/AIDS treatments and a pioneering play in molecular diagnosis.

Feb 16, 2012 10:20AM on Top StocksBy TheStockAdvisors

To overcome patent expirations, Bristol-Myers Squibb is pursing acquisitions.

Jan 30, 2012 3:13PM on Top StocksBy Minyanville

U.S. clearance is a major milestone, but Bydureon faces stiff competition from its fast-selling rival.

Jan 18, 2012 12:15PM on Top StocksBy TheStockAdvisors

This speculative biotech is a leading player in the race to commercialize genome sequencing.

Jan 9, 2012 9:37AM on Top StocksBy Gene Marcial

Positive action on new drugs by FDA in 2011 bodes well for biopharmaceuticals in 2012, and Celgene can offer long-term growth.

Dec 28, 2011 10:22AM on Top StocksBy Gene Marcial

Leadership changes at one of the world's largest and most underappreciated biotechs bode well for investors.

Dec 8, 2011 3:02PM on Top StocksBy TheStockAdvisors

The acquisition is a vote of confidence in Isis Pharmaceuticals' drug development technology.

Dec 7, 2011 7:09PM on Top StocksBy Zacks.com

The biopharmaceutical company's core product strategy is aimed at addressing major unmet medical needs.

VIDEO ON MSN MONEY

DATA PROVIDERS

Copyright © 2013 Microsoft. All rights reserved.

Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.

Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.

Japanese stock price data provided by Nomura Research Institute Ltd.; quotes delayed 20 minutes. Canadian fund data provided by CANNEX Financial Exchanges Ltd.

TOP STOCKS

The good news: the market's stumble was modest

Try as the bears might, they couldn't break U.S. stocks. But investors still face frothy prices and considerable headwinds.

More

MARKET DISPATCHES

No more Dispatches; here's where to find market news

The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.

More

SMART SPENDING

Highest drowning risk: Kids under 5

A new federal safety report shows toddlers and minority children make up a disproportionate number of drowning victims.

More

SMART TAXES

More